Reimbursement uncertainty is risk for patients, says Australian parliament inquiry
This article was originally published in Scrip
Executive Summary
Moves in Australia to delay listing new medicines on the state-funded Pharmaceutical Benefits Scheme (PBS) will have "significant consequences for the pharmaceutical sector," says a seemingly industry-sympathetic senate inquiry into recent policy changes. Companies face uncertainty in business planning and loss of investment, all of which will ultimately affect access to medicines, says the inquiry report.